Compare HFFG & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HFFG | SPRO |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.8M | 136.7M |
| IPO Year | N/A | 2017 |
| Metric | HFFG | SPRO |
|---|---|---|
| Price | $2.17 | $2.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 106.0K | ★ 258.7K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,225,541,000.00 | $40,549,000.00 |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $3.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.10 | N/A |
| 52 Week Low | $1.70 | $0.51 |
| 52 Week High | $4.93 | $3.22 |
| Indicator | HFFG | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 36.65 | 50.36 |
| Support Level | $2.16 | $2.26 |
| Resistance Level | $2.29 | $2.37 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 12.17 | 42.42 |
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The company's business consists of one operating segment; HF Group, which operates solely in the United States. The company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.